FTC Accuses Boehringer Of Subpoena Delay Tactics

Law360, New York (October 27, 2009, 7:45 PM EDT) -- The Federal Trade Commission, investigating a patent settlement between Boehringer Ingelheim Pharmaceuticals Inc. and Barr Pharmaceuticals Inc. that may have unlawfully delayed generic drug entry, has asked for a court order requiring Boehringer to comply with the terms of a subpoena.

In a petition filed Friday in the U.S. District Court for the District of Columbia, the FTC accuses Boehringer of using a number of tactics to delay the investigation, such as inappropriately redacting documents and failing to conduct a careful and thorough search.

“Nearly nine...
To view the full article, register now.

Documents

Related

Sections

Case Information

Case Title

FEDERAL TRADE COMMISSION v. BOEHRINGER INGELHEIM PHARMACEUTICALS, INC.


Case Number

1:09-mc-00564

Court

District Of Columbia

Nature of Suit

Other Statutory Actions

Judge

G. Michael Harvey

Date Filed

October 23, 2009

Companies

Government Agencies

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.